The Complementarity Effect for Cdc25 Phosphatase Inhibitors

Wassila Soufi, Meriem Merad, Faïza Boukli, Saïd Ghalem

.

DOI: 10.4236/ami.2011.12003                

Abstract

Cdc25 phosphatase have been regarded as attractive drug targets for anticancer therapies due to the correlation of their over expression with a wide variety of cancers. They are key regulators of cell cycle progression and play a central role in the checkpoint response to DNA damage. The role of Cdc25 s in cancer has become increasingly evident in recent years. More than 20 studies of patient samples are from diverse cancers show significant overexpression of Cdc25 with frequent correlation to clinical outcome. Recent screening and design efforts have yielded novel classes of inhibitors that show specificity for the Cdc25 s over other phosphatases and cause cell cycle arrest in vivo. Until now, quinone derivatives are among the most efficient inhibitors of Cdc25 phosphatase activity. Our research objective is to study the inhibition of the phosphathase Cdc25 through the molecular modeling methods.

Keywords

Cancer, Cdc25 Phosphatase, Molecular Modeling (MM, DM, and Docking), Naphtoquinone

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	K. Saad, C. Jasmin, “Substances naturelles végétales cyto-toxiques et antitumorales,” Cancer Hachette, 1979.
[2]	J. L. Amiel, Abrégé de Cancérologie Tome TI Ed Masson, 1984, 292 p.
[3]	M. Daunf, R. P. P. FllchsLa, “cancérogenèse chimique,” La recherche sur le cancer Ed Seuil Pts Sciences, 1982, pp. 27-43.
[4]	J. Kermarec, “Anatomie pathologie générale la signification biologique des lésions Tome II,” Ed. Vigot/CEF Nice, 1985, pp. 551-554.
[5]	A. Tchakline, “Le cancer problème du siècle,” Moscou Ed MIR, 1980, 195 p.
[6]	C. Quenum, R. Camatn, R. Bayelet, “Le cancer en Afrique noire épidémiologie et pathologie géographique du cancer en Afrique,” Médecine d'AL Noire, Vol. 1, No. 3, 1971, pp. 165-185.
[7]	V. Azais, Vitamine A EMC (Paris-France) Endocrinolo-gie-Nutrition The (2) 25-2ü2-F-2ü, 1995, 5 p.
[8]	J. Tredaniel, J. M. Extra, E. Lepage, P. Brice, Actualités thérapeutiques en cancérologie EMC THE (2), 25140-A10.
[9]	8 Desoize, F. Marechal, “Principes de la chimiothérapie anticancéreuse,” Le moniteur internat, n’23, pp. 47-56.
[10]	P. Poutllart, T. Palangie, M. Jouve, E. Garcia-Giralt, B. Bretalldealj, “Approche thérapeutique des cancers,” EM.C (Paris- France), Thérapeutique (2), 6 - 1984, 25140 A10, 36 p.
[11]	I. Nilsson, I. Hoffman, “Cell Cycle Regulation by the cdc25 Phosphatase Family,” Progress in Cell Cycle Re-search, Vol. 4, 2000, pp. 107-114.
[12]	K. Kristjánsdóttir and J. Rudolph, “Cdc25 Phosphatases and Cancer,” Chemistry and Biology, Vol. 11, No. 8, 2004, pp. 1043-1051. doi:10.1016/j.chembiol.2004.07.007
[13]	K. E. Pestell, A. P. Ducruet, P. Wipf and J. S. Lazo, “Synthèse totale d'un inhibiteur de phosphatases TMC-69-6H,” Oncogene, 2000, Vol. 19, pp. 6607-6612. doi:10.1038/sj.onc.1204084
[14]	J. Rudolph, “Cdc25 Phosphatases: Structure, Specificity, and Mechanism,” Biochemistry, Vol. 46, No. 12, 2007, pp. 3595-3604. doi:10.1021/bi700026j
[15]	D. Bardford, A. J. Flint and N. K. Tonks, “Crystal Structure of Human Protein Tyrosine Phosphatase 1B,” Science, Vol. 263, No. 5152, 1994, pp. 1397-1404. doi:10.1126/science.8128219
[16]	S. Herna’ndez, X. Bessa, S. Bea’, L. Herna’ndez, A. Nadal, C. Mallofre’, J. Muntane, A. Castells, P. L. Fer-na’ndez, A. Cardesa and E. Campo, “Differential Expres-sion of Cdc25 Cell-Cycle-Activating Phosphatases in Human Colorectal Carcinoma,” Laboratory Investigation, Vol. 81, 2001, pp. 465-473.
[17]	I. Takemara, H. Yamamoto, M. Sekimoto, M. Ohue, S. Noura, Y. Miyake, T. Matsumoto, T. Aihara, N. Tomita, Y. Tamaki, I. Sakita, N. Kikkawa, N. Matsuura, H. Shiozaki and M. Monden, “Overexpression of Cdc25B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma,” Cancer Research, Vol. 60, 2000, pp. 3043-3050.
[18]	E. S. W. Ngan, Y. Hashimoto, X.-Q. Ma, M. J. Tsai and S. Y. Tsai, “Overexpression of Cdc25B, an Androgen Re-ceptor Coactivator, in Prostate Cancer,” Oncogene, Vol. 22, 2003, pp. 734-739. doi:10.1038/sj.onc.1206121
[19]	W. G. Wu, Y. H. Fan, B. L. Kemp, G. Walsh and L. Mao, “Overexpression of Cdc25A and cdc25B Is Frequent in Primary Nonsmall Cell Lung Cancer But Is Not Asso-ciated with Overexpression of C-myc,” Cancer Research, Vol. 58, No. 18, 1998, pp. 4082-4085.
[20]	H. Sasaki, H. Yukiue, Y. Kobayashi, M. Tanahashi, S. Moriyama, Y. Nakashima, I. Fukai, M. Kiriyama, Y. Yamakawa and Y. Fujii, “Expression of the Cdc25B Gene as a Prognosis Marker in Non-Small Cell Lung Cancer,” Cancer Letters, Vol. 173, No. 2, 2001, pp. 187- 192. doi:10.1016/S0304-3835(01)00669-3
[21]	K. Kristjansdottir and J. Rudolph, “Cdc25 Phosphatases and Cancer,” Chemistry & Biology, Vol. 11, No. 8, 2004, pp. 1043-1051. doi:10.1016/j.chembiol.2004.07.007
[22]	K. Galaktionov, A. K. Lee, J. Eckstein, G. Draetta, J. Meckler, M. Loda and D. Beach, “Cdc25 Phosphatases as Potential Human Oncogenes,” Science, Vol. 269, No. 5230, 1995, pp. 1575-1577. doi:10.1126/science.7667636
[23]	A. Fernandez-Vidal, L. Ysebaert, C. Didier, R. Betous, F. D. Toni, N. Prade-Houdellier, C. Demur, M.-O. Con-tour-Galce′ra, G. P. Pre′vost, B. Ducommun, B. Payrastre, C. Racaud-Sultan and S. Manenti, “Cell Adhesion Regu-lates Cdc25A Expression and Proliferation in Acute Myeloid Leukemia,” Cancer Research, Vol. 66, No. 14, 2006, pp. 7128-7135. doi:10.1158/0008-5472.CAN-05-2552
[24]	Y. Nishikawa, B. I. Carr, M. Wang, S. Kar, F. Finn, B. Dowd, Z. B. Zheng, J. Kerns and S. Naganathan, “Growth Inhibition of Hepatoma Cells Induced by Vi-tamin K and Its Analogs,” Journal of Biological Chemistry, Vol. 270, No. 47, 1995, pp. 28304-28310. doi:10.1074/jbc.270.47.28304
[25]	R. Boutros, C. Dozier and B. Ducommun, “The When and Wheres of Cdc25 Phosphatases,” Current Opinion in Cell Biology, Vol. 18, No. 2, 2006, pp. 185-191. doi:10.1016/j.ceb.2006.02.003
[26]	E. B. Fauman, J. P. Cogswell, B. Lovejoy, W. J. Rocque, W. Holmes, V. G. Montana, H. Piwnica-Worms, M. J. Rink and M. A. Saper, “Crystal Structure of the Catalytic Domain of the Human Cell Cycle Control Phosphatase, Cdc25A,” Cell, Vol. 93, No. 4, 1998, pp. 617-625. doi:10.1016/S0092-8674(00)81190-3
[27]	R. A. Reynolds, A. W. Yem, C. L. Wolfe, M. R. Deibel, C. G. Chidester and K. D. Watenpaugh, “Crystal Structure of the Catalytic Subunit of Cdc25B Required for G2/M Phase Transition of the Cell Cycle,” Journal of Molecular Biology, Vol. 293, No. 3, 1999, pp. 559-568. doi:10.1006/jmbi.1999.3168
[28]	M.-O. Contour-Galce′ra, A. Sidhu, G. Pre′vost, D. Bigg and B. Ducommun, “What’s New on Cdc25 Phosphatase Inhibitors,” Pharmacology & Therapeutics, Vol. 115, No. 1, 2007, pp. 1-12. doi:10.1016/j.pharmthera.2007.03.009
[29]	G. P. Prevost, M.-C. Brezak, F. Goubin, O. Mondesert, M.-O. Galcera, M. Quaranta, F. Alby, O. Lavergne and B. Ducommun, “Inhibitors of theCdc25 Phosphatases,” Progress in Cell Cycle Research, Vol. 5, 2003, pp. 225-234.
[30]	J. Rudolph, “Inhibiting Transient Protein–Protein Interac-tions: Lessons from the Cdc25 Protein Tyrosine Phos-phatases,” Nature Reviews Cancer, Vol. 7, No. 3, 2007, pp. 202-211.
[31]	R. Boutros, V. Lobjois and B. Ducommun, “CDC25 Phosphatases in Cancer Cells: Key Players? Good Tar-gets?” Nature Reviews Cancer, Vol. 7, No. 8, 2007, pp. 495-507. doi:10.1038/nrc2169
[32]	S. Cao, C. Foster, M. Brisson, J. S. Lazo, D. G. Kingston, I. Bioorg, “Evaluation biologique de l’inhibition des-phosphatases cdc25 dans des lignées d’adénocarcinomes mammaires humains,” Journal of Medicinal Chemistry, Vol. 13, No. 4, 2005, pp. 999-1003
[33]	S. P. Gunasekera, P. J. McCarty and M. Kelly-Borges, “Studies in Natural Products Chemistry: Bioactive Natural Products,” Journal of the American Chemical Society, Vol. 118, No. 36, 1996, pp. 8759-8760. doi:10.1021/ja961961+
[34]	R. E. Cebula, J. L. Blanchard, M. D. Boisclair, K. Pal and N. J. Bockovich, Bioorganic & Medicinal Chemistry Let-ters, Vol. 7, No. 15, 1997, pp. 2015-2020. doi:10.1016/S0960-894X(97)00357-0
[35]	D. R. John and C. C. Marjorie, “Chimie Organique Mod-erne,” Merck Index, 11th Edition, 1975, p. 651.
[36]	R. G. Ewan, Y. Xiong, J. Melanie, L. D’andrea and Lynne Regan, “Design of Stable α-Helical Arrays from an Ideal-ized TPR Motif,” Elsevier Science Ltd., Vol. 11, 2003, pp. 497-508.